サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1764275

去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療の世界市場レポート 2025年

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療の世界市場レポート 2025年
出版日: 2025年07月07日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.6％で104億8,000万米ドルに成長します。予測期間中に予測される成長は、精密腫瘍学とバイオマーカー主導型治療の採用の増加、次世代ホルモン治療と放射性リガンド治療に対する需要の高まり、進行前立腺がんに対する臨床検査パイプラインの拡大、標的と免疫腫瘍学薬剤のパイプラインの成長、個別化医療戦略に対する需要の高まりに起因すると考えられます。この期間に予想される主要動向には、免疫療法併用レジメンの開発、臨床的意思決定へのゲノムプロファイリングの導入、患者モニタリングへのデジタルヘルスツールの活用、二重特異性T細胞エンゲージャーの革新、腫瘍微小環境モジュレーターの進歩などがあります。

前立腺がんの有病率の増加は、今後数年間の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場の成長を促進すると予想されます。前立腺がんは、膀胱の下と直腸の前に位置する男性の小さな臓器である前立腺に発生するがんの一形態です。前立腺がんの開発には、高齢化が大きく寄与しています。去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療は、標準的なホルモン療法が効かなくなった進行期の前立腺がんの治療に用いられます。これらの治療は、病気の進行を遅らせ、症状を管理し、生活の質を向上させることによって、患者の予後を改善します。例えば、2024年11月、英国の政府機関であるNational Health Serviceは、2022年の新規前立腺がん症例が5万4,732例に達し、2021年と比較して1万1,354例増加したと報告しました。したがって、前立腺がんの有病率の上昇がCRPC/HRPCA治療市場の成長を促進しています。

去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場の主要企業は、治療効果と患者の転帰を改善するために、革新的な製品の開拓と、デュアルアクション錠などの薬事承認の確保に注力しています。デュアルアクション錠は、1回の投与で2つの治療を組み合わせ、CRPCの治療に関与する複数の経路を同時に標的とする先進的な製剤です。例えば、ベルギーに本社を置く製薬会社ヤンセン・ファーマシューティカルズは、2023年8月、BRCA遺伝子変異を有する転移性去勢抵抗性前立腺がん（mCRPC）の成人患者を対象とした新しい錠剤「アキーガ」の承認を米国食品医薬品局（FDA）から取得しました。アキーガは、PARP阻害剤（ニラパリブ）とCYP17阻害剤（酢酸アビラテロン）を統合したプレシジョン・メディシンで、特にBRCA遺伝子変異患者を対象としています。プレドニゾンと併用することで、標準的なホルモン療法と比較して、放射線学的無増悪生存期間（rPFS）を有意に改善します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場：成長率分析
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場の実績：規模と成長、2019～2024年
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場の予測：規模と成長、2024～2029年、2034年
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療：総潜在市場規模（TAM）

第6章 市場セグメンテーション

  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ホルモン療法
  • 化学療法
  • 免疫療法
  • 標的療法
  • 放射線治療
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
  • 経口
  • 注射剤
  • 静脈内
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • 腫瘍学センター
  • 外来手術センター
  • その他
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場、ホルモン療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • アンドロゲン受容体（AR）阻害剤
  • アンドロゲン合成阻害剤
  • 黄体形成ホルモン放出ホルモン（LHRH）作動薬/拮抗薬
  • ゴナドトロピン放出ホルモン（GnRH）アゴニスト/アンタゴニスト
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場、化学療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • タキサン
  • プラチナベースの薬剤
  • その他の化学療法
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場、免疫療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 免疫チェックポイント阻害剤
  • がんワクチン
  • サイトカイン療法
  • 養子細胞療法
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場、標的療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ポリADP-リボースポリメラーゼ（PARP）阻害剤
  • ホスホイノシチド3キナーゼ（PI3K）/タンパク質キナーゼB（PI3K）/哺乳類ラパマイシン標的（mTOR）阻害剤
  • チロシンキナーゼ阻害剤（TKI）
  • デオキシリボ核酸損傷応答（DDR）阻害剤
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場、放射線治療のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 外部放射線療法
  • 近接放射線療法
  • 放射性医薬品

第7章 地域別・国別分析

  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場：競合情勢
  • 去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場：企業プロファイル
    • Pfizer Inc.
    • Johnson And Johnson
    • Merck & Co. Inc.
    • Bayer AG
    • Novartis AG

第31章 その他の大手企業と革新的企業

  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma Inc.
  • Daiichi Sankyo Co. Ltd.
  • Lantheus Holdings Inc.
  • POINT Biopharma Global Inc.
  • Clovis Oncology Inc.
  • Arvinas Inc.
  • Clarity Pharmaceuticals Ltd
  • Modra Pharmaceuticals B.V.
  • Oncternal Therapeutics Inc.
  • Zenith Epigenetics Ltd.
  • ESSA Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場、2029年：新たな機会を提供する国
  • 去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場、2029年：新たな機会を提供するセグメント
  • 去勢抵抗性前立腺がん（CRPC）/ホルモン抵抗性前立腺がん（HRPCA）治療市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35863

Castration-resistant prostate cancer (CRPC), also known as hormone-refractory prostate cancer (HRPCA), therapeutics include drugs and treatments designed for CRPC-an advanced stage of prostate cancer that continues to advance despite reduced testosterone levels, typically following androgen deprivation therapy. These treatments are intended to address resistance mechanisms, enhance patient outcomes, and prolong survival.

The primary therapy types for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) include hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Hormonal therapy involves using hormones or hormone-blocking medications to inhibit or slow the growth of hormone-sensitive cancers. These treatments are delivered through oral, injectable, and intravenous methods and are utilized by various end users, such as hospitals, oncology centers, ambulatory surgical centers, and others.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market research report is one of a series of new reports from The Business Research Company that provides castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market statistics, including the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics industry's global market size, regional shares, competitors with the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market share, detailed castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market. This castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market size has grown strongly in recent years. It will grow from $7.96 billion in 2024 to $8.43 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to the rising incidence of prostate cancer, increased use of androgen deprivation therapy (ADT) resulting in resistance, expanded availability of targeted therapy options, advancements in diagnostic imaging capabilities, and growing healthcare investments in oncology infrastructure.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market size is expected to see strong growth in the next few years. It will grow to $10.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The projected growth during the forecast period can be attributed to the increasing adoption of precision oncology and biomarker-driven therapies, rising demand for next-generation hormonal treatments and radioligand therapy, an expanding clinical trial pipeline for advanced prostate cancer, a growing pipeline of targeted and immuno-oncology agents, and a heightened demand for personalized medicine strategies. Key trends expected during this period include the development of combination immunotherapy regimens, the incorporation of genomic profiling into clinical decision-making, the use of digital health tools for patient monitoring, innovations in bispecific T-cell engagers, and advancements in tumor microenvironment modulators.

The increasing prevalence of prostate cancer is anticipated to drive the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in the coming years. Prostate cancer is a form of cancer that originates in the prostate gland, a small organ in men located beneath the bladder and in front of the rectum. The growing prevalence of prostate cancer is largely attributed to the aging population, as the likelihood of developing the disease rises significantly with age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics are used to treat advanced stages of prostate cancer that no longer respond to standard hormone therapy. These treatments enhance patient outcomes by slowing disease progression, managing symptoms, and improving quality of life. For example, in November 2024, the National Health Service, a government agency in the UK, reported that new prostate cancer cases reached 54,732 in 2022, reflecting an increase of 11,354 cases compared to 2021. Hence, the rising prevalence of prostate cancer is fueling the growth of the CRPC or HRPCA therapeutics market.

Leading companies in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are concentrating on the development of innovative products and securing regulatory approvals, such as dual-action tablets, to improve treatment effectiveness and patient outcomes. Dual-action tablets are advanced formulations that combine two therapeutic agents in a single dose to concurrently target multiple pathways involved in the treatment of CRPC. For example, in August 2023, Janssen Pharmaceuticals, a pharmaceutical company based in Belgium, received approval from the U.S. Food and Drug Administration (FDA) for Akeega, a new tablet designed for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that integrates a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically aimed at patients with BRCA mutations. When administered with prednisone, it significantly improves radiographic progression-free survival (rPFS) compared to standard hormonal therapies.

In June 2024, AstraZeneca plc, a pharmaceutical company based in the US, acquired Fusion Pharmaceuticals Inc. for an undisclosed sum. Through this acquisition, AstraZeneca seeks to revolutionize cancer treatment and outcomes by shifting from conventional chemotherapy and radiotherapy to more precise next-generation radioconjugate therapies. Fusion Pharmaceuticals Inc., a biotech firm headquartered in Canada, is actively developing FPI-2265, a targeted alpha therapy intended for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Major players in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market consists of sales of enzalutamide, darolutamide, abiraterone, and cabazitaxel. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Therapy Type: Hormonal Therapy; Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy
  • 2) By Route Of Administration: Oral; Injectable; Intravenous
  • 3) By End User: Hospitals; Oncology Centers; Ambulatory Surgical Centers; Other End Users
  • Subsegments:
  • 1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors; Androgen Synthesis Inhibitors; Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists; Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
  • 2) By Chemotherapy: Taxanes; Platinum-Based Agents; Other Chemotherapies
  • 3) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines; Cytokine Therapy; Adoptive Cell Therapy
  • 4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors; Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors; Tyrosine Kinase Inhibitors (TKIs); Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
  • 5) By Radiation Therapy: External Beam Radiation Therapy; Brachytherapy; Radiopharmaceuticals
  • Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Merck & Co. Inc.; Bayer AG; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Characteristics

3. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Trends And Strategies

4. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Growth Rate Analysis
  • 5.4. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Total Addressable Market (TAM)

6. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Segmentation

  • 6.1. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hormonal Therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy
  • 6.2. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Injectable
  • Intravenous
  • 6.3. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Oncology Centers
  • Ambulatory Surgical Centers
  • Other End Users
  • 6.4. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Androgen Receptor (AR) Inhibitors
  • Androgen Synthesis Inhibitors
  • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists
  • Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
  • 6.5. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Taxanes
  • Platinum-Based Agents
  • Other Chemotherapies
  • 6.6. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immune Checkpoint Inhibitors
  • Cancer Vaccines
  • Cytokine Therapy
  • Adoptive Cell Therapy
  • 6.7. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Poly ADP-Ribose Polymerase (PARP) Inhibitors
  • Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors
  • Tyrosine Kinase Inhibitors (TKIs)
  • Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
  • 6.8. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • External Beam Radiation Therapy
  • Brachytherapy
  • Radiopharmaceuticals

7. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Regional And Country Analysis

  • 7.1. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 8.1. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 9.1. China Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • 9.2. China Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 10.1. India Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 11.1. Japan Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • 11.2. Japan Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 12.1. Australia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 13.1. Indonesia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 14.1. South Korea Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • 14.2. South Korea Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 15.1. Western Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • 15.2. Western Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 16.1. UK Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 17.1. Germany Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 18.1. France Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 19.1. Italy Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 20.1. Spain Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 21.1. Eastern Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • 21.2. Eastern Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 22.1. Russia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 23.1. North America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • 23.2. North America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 24.1. USA Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • 24.2. USA Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 25.1. Canada Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • 25.2. Canada Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 26.1. South America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • 26.2. South America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 27.1. Brazil Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 28.1. Middle East Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • 28.2. Middle East Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

  • 29.1. Africa Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Overview
  • 29.2. Africa Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Competitive Landscape
  • 30.2. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. Bristol-Myers Squibb Company
  • 31.3. AstraZeneca plc
  • 31.4. Takeda Pharmaceutical Company Limited
  • 31.5. Astellas Pharma Inc.
  • 31.6. Daiichi Sankyo Co. Ltd.
  • 31.7. Lantheus Holdings Inc.
  • 31.8. POINT Biopharma Global Inc.
  • 31.9. Clovis Oncology Inc.
  • 31.10. Arvinas Inc.
  • 31.11. Clarity Pharmaceuticals Ltd
  • 31.12. Modra Pharmaceuticals B.V.
  • 31.13. Oncternal Therapeutics Inc.
  • 31.14. Zenith Epigenetics Ltd.
  • 31.15. ESSA Pharma Inc.

32. Global Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

34. Recent Developments In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market

35. Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market High Potential Countries, Segments and Strategies

  • 35.1 Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer